论文部分内容阅读
目的评价新一代氟喹诺酮类药物莫西沙星对耐多药肺结核病(MDR-TB)的治疗作用。方法将62例MDR-TB患者随机平分为两组:治疗组用莫西沙星0.4 g/d,对照组用左氧氟沙星0.2 g,每天3次,疗程12个月,同时辅以其他抗结核药物治疗。结果有效率治疗组90.3%,优于对照组77.4%;痰菌阴转率治疗组87.1%,优于对照组74.2%;两组不良反应轻微,差异无统计学意义。结论莫西沙星是一种安全有效的抗结核药物。
Objective To evaluate the therapeutic effect of a new generation of fluoroquinolone moxifloxacin on multidrug-resistant pulmonary tuberculosis (MDR-TB). Methods Sixty-two MDR-TB patients were randomly divided into two groups: moxifloxacin 0.4 g / d in the treatment group and 0.2 g levofloxacin in the control group three times daily for 12 months, supplemented with other anti-TB drugs. Results The effective treatment group 90.3%, better than the control group 77.4%; sputum negative conversion rate treatment group 87.1%, better than the control group 74.2%; two groups of mild adverse reactions, the difference was not statistically significant. Conclusion Moxifloxacin is a safe and effective anti-TB drug.